Dr. Janet Chollet

Dr. Janet Chollet has established a career shaped by clinical practice, translational science, and the development of therapeutic programs that address meaningful gaps in women’s health. She is a board-certified obstetrician–gynecologist and serves as the Co-Founder and Chief Medical Officer of Procyrn LLC, where she directs efforts to create sustained-release biologics and reformulated antivirals. Her work centers on maternal–fetal health, neuroinflammation, and HPV-related cervical disease, reflecting a steady commitment to solutions that can be realistically advanced into clinical care. Across more than three decades in medicine, she has contributed to patient care, academic instruction, and early therapeutic development at institutions such as Beth Israel Deaconess Medical Center and the University of Pittsburgh. Her experience includes three U.S. patents in drug-delivery innovation and participation in several early-stage programs that bridge scientific insight with clinical needs. These efforts demonstrate how sustained engagement in both practice and research can support the development of therapies designed for real-world use. Her academic path began with a Bachelor of Science in Neuroscience from the University of California, Santa Barbara. She earned her medical degree from New York Medical College and completed her residency in Obstetrics and Gynecology at LAC/USC Women’s Hospital. The intensity of training during those years strengthened her long-term focus on supporting women, children, and families through complex medical conditions. This foundation later led her to develop an interest in translational approaches that integrate clinical relevance with scientific rigor. After residency, she joined Magee-Women’s Hospital as a staff physician and instructor, balancing hands-on patient care with clinical teaching. She later continued her work at Beth Israel Deaconess Medical Center, where she combined academic involvement with an expanding interest in therapeutic development. Earlier in her career, she co-founded Pear Tree Pharmaceuticals and served as Vice President of Clinical Affairs, contributing to drug-delivery technologies that supported the company’s merger with Dare Bioscience. In 2023, she co-founded Procyrn LLC, guiding clinical development and regulatory planning for programs targeting hypertensive disorders of pregnancy, immune-modulating approaches for ALS, and selective therapeutics for HPV-driven dysplasia. She also evaluates exploratory concepts related to maternal–fetal immune stabilization and its potential influence on neurodevelopment. Her leadership emphasizes reproducible preclinical models, clear decision points, and disciplined advancement of promising ideas. Her career also includes early creative work, including co-writing an Emmy-winning television episode. Outside of professional responsibilities, she values family, wellness, travel, and creative expression, and continues to explore how emerging technologies can strengthen clinical processes. Dr. Janet Chollet remains dedicated to advancing therapies that translate scientific understanding into meaningful patient benefit.